ObsEva nominates Stephanie Brown for election to its Board of Directors

– SWITZERLAND, Geneva –  ObsEva SA (SIX: OBSN | NASDAQ: OBSV), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the nomination of Stephanie Brown for election to its Board of Directors at the 2022 AGM, bringing valuable commercial expertise and industry insight to the Board.

Effective December 1, 2021, she will join the Board of Directors as an Observer.

The company also announced that Dr. Jacky Vonderscher has decided to step down from the Board effective 19 November 2021.

“It is a pleasure to welcome Stephanie, an esteemed industry leader, to our Board of Directors. Stephanie has a strong track record for building and transforming businesses with successful outcomes, translating organizational vision, and enhancing operational capabilities,” said Board Chairman, Dr. Frank Verwiel.

He added: “ She has deep experience in product launches and has brought highly specialized, breakthrough therapeutics from clinic to commercialization across many indications. Her strategic agility and diverse background will be invaluable as we execute on our path forward, continue to pursue regulatory approvals, and advance linzagolix towards commercialization—with the goal of ultimately offering more individualized treatment options for a broader range of women. I, along with ObsEva’s entire board and leadership team, look forward to working with Stephanie.”

About Stephanie Brown

Ms. Brown brings over 30 years of experience in executive leadership with broad commercial expertise and accomplishments in the biopharma industry. In her executive-level roles, her responsibilities have included commercial assessments and recommendations for business development, product development, and portfolio planning. Most recently, Ms. Brown served as SVP and Head of the Rare Diseases Franchise, North America at Ipsen Pharmaceuticals. In this role, she was responsible for driving strategy, execution, revenue, and profit for the rare diseases portfolio. She built the rare diseases business unit with responsibility for commercialization of in-line and launch brands including direction of marketing, sales, patient services, and excellence operations, in addition to oversight of all other key commercial functions at Ipsen. Before Ipsen, Ms. Brown was VP and US Head of Novartis’ Neuroscience Franchise with responsibility for commercial marketing, sales, and operations, and had oversight of market access, patient services, and medical affairs. Earlier in her career, Ms. Brown held various elevating leadership roles at Takeda Pharmaceuticals US, Biogen, Genentech, and Merck. Ms. Brown has chaired and governed inter-company collaborations and has chaired, co-chaired, and served on multiple executive US and global governance committees. She has extensive Board experience and is currently an active member of the Board of Directors of the Biotechnology Innovation Organization, a biotechnology industry association in the US.

Ms. Brown said, “I am delighted to join ObsEva, whose positive data from the Phase 3 PRIMROSE study suggests linzagolix has the potential to combine strong efficacy, favorable tolerability and offer unique dosing options for uterine fibroids. If approved, linzagolix would be the first and only GnRH receptor antagonist with a low dose option to address the needs of women who cannot or do not want to take hormones. I am incredibly excited about the potential of bringing this differentiated treatment to market, and I look forward to working with ObsEva’s exceptional team to advance the company’s mission.”

Ms. Brown earned a B.S. in Chemistry with Biology from Mount Allison University, Canada, and an MBA from Heriot-Watt University, Scotland.

About Obseva

Obseva is a biopharmaceutical company built to address some of the most challenging unmet needs in women’s health – an under-researched, under-invested field of medicine. With deep expertise in clinical development, Obseva is passionate about the pursuit of advances that benefit women and their health and the importance of delivering truly meaningful innovation in this space. Through strategic in-licensing and disciplined drug development, Obseva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. Obseva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”.

For more information: https://www.obseva.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team